GlassScriptPhysician profile
James R Anderson
NPI 1184620460
$10,061.83
in general payments reported to CMS, 2019-2025
51 companies · $965 in 2025
The $965 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $2,155 · 2021: $1,550 · 2022: $1,526 · 2023: $1,186 · 2024: $828 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,332.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,180.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $918.70 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $525.45 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.29 | 2019-2025 | Jardiance |
| Pfizer INC. | $421.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.08 | 2020-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $409.80 | 2019-2020 | |
| Amgen INC. | $376.08 | 2019-2024 | Evenity, Prolia, Repatha |
| Supernus Pharmaceuticals, INC. | $347.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $344.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $332.34 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $286.82 | 2019-2025 | Veozah |
| Abbott Laboratories | $278.92 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $265.18 | 2023-2025 | Gemtesa, Aptiom |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.